Andre Van Maurik

Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Sjögren's disease metabolome reveals biomarker signatures to characterise patients and assess disease activity.

Sjögren's disease metabolome reveals biomarker signatures to characterise patients and assess disease activity.

Journal: RMD open

Published: August 30, 2025

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.

Journal: Kidney international

Published: May 14, 2025

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial.

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial.

Journal: Arthritis care & research

Published: March 14, 2025

Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).

Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).

Journal: Annals of the rheumatic diseases

Published: February 17, 2025

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Journal: Annals of the rheumatic diseases

Published: February 16, 2024

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Journal: Rheumatology (Oxford, England)

Published: December 01, 2023

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.

Journal: Trials

Published: October 06, 2022

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.

Journal: JCI insight

Published: June 24, 2022

Population model-based analysis of the memory B-cell response following belimumab therapy in the treatment of systemic lupus erythematosus.

Population model-based analysis of the memory B-cell response following belimumab therapy in the treatment of systemic lupus erythematosus.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 29, 2022

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.

Journal: Diabetologia

Published: May 14, 2020

Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome.

Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome.

Journal: Rheumatology (Oxford, England)

Published: April 22, 2020

Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren's syndrome is associated with B cell hyperactivity and type I interferon activity.

Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren's syndrome is associated with B cell hyperactivity and type I interferon activity.

Journal: RMD open

Published: January 15, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026